-
Pioneering Epigenetic MedicineDedicate to developing next-generation gene modulation therapy utilizing regulation of epigenetic genome for a variety of human diseases
Epigenetic modulation
Epigenetic modulation is a key mechanism for gene regulation in almost all organisms. It is stable, heritable and serves as a basis for a single fertilized egg to develop into a multi-organ individual. Epigenic Therapeutics developed an Epigenetic Modulator, a platform that utilizes nuclease-inactivated dead Cas protein and epi-enzymes to precisely control gene expression to cure diseases without any DNA cutting, nicking or altering.
Technology Advantages
-
High efficiency
Effectively inhibit the expression of targeted genes
-
Great durability
One single-course treatment lasts for years
-
Non-vial delivery
Optimized and proprietary LNP formulation confers low toxicity and organ specificity
-
Favorable safety
No chromosomal abnormalities and no detected off-target effect
-
Cost effective
Streamlined process with controllable cost
Latest news
Epigenic Therapeutics Announced $32 Million in Series A Funding to Bring Breakthrough Epigenetic Medicine to Clinical Development
-
Press Releases2024/09/02Epigenic Therapeutics Announced to be listed in“Forbes Asia 100 To Watch 2024”
-
Press Releases2024/05/01Epigenic Therapeutics to present preclinical update of company's epigenome modulation technology for elimination of HBV viral antigens at 2024 annual conference of the European Association for the Study of the Liver
-
Press Releases2023/10/28Epigenic Therapeutics to Present Company's Epigenetic Modulation Technology in Enhancement of CAR-T Function at SITC 2023
-
Press Releases2023/10/20Epigenic Therapeutics to Present Company's Leading Drug Discovery Program Using Epigenetic Modulation Technology at ESGCT 2023
-
Press Releases2023/09/28Epigenic Therapeutics to Participate in the Chardan 7th Annual Genetic Medicines Conference
-
Press Releases2023/08/30Epigenic Therapeutics Announces $32 Million in Series A Funding to Bring Breakthrough Epigenome Medicine to Clinical Development
-
Press Releases2022/08/07Epigenic Therapeutics Raises $20 Million in Series Angel and Pre-A Funding to Advance Next Generation Gene Editing Therapy
Along with your contribution, we are committed to benefiting patients living with hard-to-treat diseases
Human resources are the core competitiveness of an enterprise. Epigenic Therapeutics established a vibrant, professional and creative team to continuously optimize our technology platforms and to develop innovative medicines. We continuously provide the diversity of career development and a better workplace for our employees, as well as facilitating team coordination and creating value in order to achieve the common development of Epigenic Therapeutics and employees.
